MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators

The use of peptides as drugs has progressed over time and continues to evolve as treatment paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has shown great promise for the treatment of muscle wasting diseases. Here, we report the MSTN-derived novel peptides MIF1 (10-...

Full description

Bibliographic Details
Main Authors: Ahmad, K. (Author), Ahmad, S.S (Author), Ali, S. (Author), Baig, M.H (Author), Choi, I. (Author), Lee, E.J (Author), Lim, J.H (Author), Park, S.-Y (Author), Shaikh, S. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
Online Access:View Fulltext in Publisher